References
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78. doi:10.1016/S0140-6736(20)31604-4.
- Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy following COVID-19 vaccination: imaging findings review. Acad Radiol. 2021:S1076-6332(21)00196–3. Published online May 1. doi:10.1016/j.acra.2021.04.007.
- McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 vaccination-related uptake on FDG PET/CT: an emerging dilemma and suggestions for management. AJR Am J Roentgenol. 2021;217(4):975–83. Published online March 1. doi:10.2214/AJR.21.25728.
- Abou-Foul AK, Ross E, Abou-Foul M. George AP. P-257 Cervical lymphadenopathy following COVID-19 vaccine: clinical characteristics and implications for head and neck cancer services. Oral Oncol. 2021;118:20. doi:10.1016/S1368-8375(21)00540-6.
- Özütemiz C, Krystosek LA, Church AL, Chauhan A, Ellermann JM, Domingo-Musibay E, Steinberger D. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients. Radiology. 2021;300(1):E296–E300. doi:10.1148/radiol.2021210275.
- Burger IA, Husmann L, Hany TF, Schmid DT, Schaefer NG. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin Nucl Med. 2011;36(10):848–53. doi:10.1097/RLU.0b013e3182177322.
- Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A. Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination. Pharmacotherapy. 2008;28(9):1194–97. doi:10.1592/phco.28.9.1194.
- Local reactions, systemic reactions, adverse events, and serious adverse events: Janssen COVID-19 vaccine (J&J) | CDC. Published March 2, 2021. [accessed 2021 July 17]. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html.
- Reactions and adverse events of the pfizer-BioNTech COVID-19 vaccine | CDC. Published May 14, 2021. [accessed 2021 July 17]. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.
- Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imag. 2021;48(6):1854–63. doi:10.1007/s00259-021-05314-2.
- Cohen D, Hazut Krauthammer S, Cohen YC, Perry C, Avivi I, Herishanu Y, Even-Sapir E. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur J Nucl Med Mol Imag. 2021;48(11):3540–49. Published online May 8. doi:10.1007/s00259-021-05389-x.
- Shah S, Wagner T, Nathan M, Szyszko T. COVID-19 vaccine-related lymph node activation - patterns of uptake on PET-CT. BJR Case Rep. 2021;7(3):20210040. doi:10.1259/bjrcr.20210040.
- Xu G, Lu Y. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET/CT. Clin Nucl Med. 2021;46(4):353–54. doi:10.1097/RLU.0000000000003597.
- Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19–iv29. doi:10.1093/annonc/mdy080.
- Nawwar AA, Searle J, Singh R, Lyburn ID. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding. Eur J Nucl Med Mol Imag. 2021;48(8):2657–58. doi:10.1007/s00259-021-05279-2.
- Nawwar AA, Searle J, Hopkins R, Lyburn ID. False-positive axillary lymph nodes on FDG PET/CT resulting from COVID-19 immunization. Clin Nucl Med. 2021. Published online April 21. doi:10.1097/RLU.0000000000003657.
- SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf. [accessed 2021 July 17]. https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf.
- Becker AS, Perez-Johnston R, Chikarmane SA, Chen, MM, El Homsi, M, Feigin, KN, Gallagher, KM, Hanna, EY, Hicks, M, Ilica, AT, et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology. 2021:210436. Published online February 24. doi:10.1148/radiol.2021210436.